Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Citracal ad claims

This article was originally published in The Tan Sheet

Executive Summary

National Advertising Division of the Council of Better Business Bureaus concludes unqualified marketing claims that Mission Pharmacal's Citracal is "better absorbed than calcium carbonate" should be discontinued. Group also found superior solubility claims made in the absence of superior absorption statements would be supported by the firm's in vitro data if "carefully qualified." Concluded May 5, inquiry was prompted by GlaxoSmithKline, marketer of OsCal supplements with calcium carbonate. NAD's recommendations reflect and confirm January decision by National Advertising Review Board regarding similar Citracal claims and supporting data. That case involved a challenge by Caltrate marketer Wyeth Consumer Healthcare (1"The Tan Sheet" Aug. 5, 2002, p. 7)...

You may also be interested in...

Citracal Quantified Calcium Absorption Superiority Claims Unproven – NAD

Quantified claims that Mission Pharmacal's Citracal calcium supplement is better absorbed than calcium carbonate are not supported by the submitted clinical trials and should be discontinued, NAD concludes in an upcoming NAD Case Reports

US House Co-signs Banking For Hemp Industry

House passes “SAFE Banking” Act sponsored by Rep. Ed Perlmutter to allow cannabis- and hemp-related businesses in states with some form of legalized marijuana to access financial services by creating protections for those institutions. Sen. Jeff Merkley introduced the same legislation in March.

ObvioHealth Is Building A New Digital Ecosystem To 'Revolutionize' Trials

Using artificial intelligence and strict data collection protocol, ObvioHealth hopes to digitize clinical trials with the assistance of medical devices and consumer technology.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts